Abstract:Heart failure with preserved ejection fraction (HFpEF) is the most predominant form of heart failure in the United States. This multi‐system pathology results in a 5‐year mortality rate for which there are very few treatment options. The obese ZSF1 rat model has previously been shown to recapitulate much of the human phenotype including obesity, metabolic syndrome, diabetes, and hypertension. In this study, we investigated the complex and largely unknown role of abnormal nitric oxide signaling and nitrosative stress in the pathobiology of HFpEF. Male ZSF1 rats and normotensive controls of Wistar Kyoto (WKY) background strain (n=7 each group) were studied at 10, 14 and 18 weeks of age to monitor disease progression and alterations in nitric oxide signaling. Cardiac protein nitrosylation (RxNO) was measured by chemiluminescence. Analysis of circulating plasma nitrite bioavailability was performed using high performance liquid chromatography. GSNOR, one of the enzymes that degrade nitrosothiols, mRNA expression was measured and plotted as relative fold difference to WKY expression in this model of cardiometabolic HFpEF. ZSF1 rats exhibited significantly increased cardiac protein nitrosylation as the HFpEF phenotype progressed from 10 to 18 weeks of age as compared to the WKY rat group. GSNOR mRNA expression was significantly decreased in the ZSF1 rat relative to the WKY at all time points. During the later 18‐week timepont, cardiac GSNOR activity was found to be decreased compared to that of the WKY. Circulating plasma nitrite, a measure of eNOS function, was decreased in the ZSF1 rat at 14 and 18 weeks compared to the WKY at subsequent aging timepoints. These data correlate to an increasing left ventricular end diastolic pressure (LVEDP) and decreased vascular relaxation as the ZSF1 animals age and develop more severe HFpEF disease pathology. Our data suggests that nitric oxide signaling is dysregulated in the setting of HFpEF resulting in a significant increase in cardiac protein nitrosylation coupled with a reduction in circulating nitrite and NO signaling in the vasculature. Excessive cardiac nitrosative stress resulting in pathological myocardial signaling has been previously implicated as a driver of HFpEF. Reduced vascular nitrite bioavailability resulting in attenuated physiological NO signaling could account for the profound vascular dysfunction observed in HFpEF patients. Future studies are aimed at the further elucidation of the role of various NO storage pools in HFpEF.

Increased Nitrosoglutathione Reductase Activity in Hypoxic Pulmonary Hypertension in Mice

[Relationship Between Expression of Endothelial Nitric Oxide Synthase and NADPH Oxidase in Lungs of Mice Exposed to Chronic Hypoxia].

Expressions of NOX4 and eNOS in pulmonary vasculature in mouse model of chronic hypoxia

[Interaction Between Endogenous Nitric Oxide and Hydrogen Sulfide in Pathogenesis of Hypoxic Pulmonary Hypertension].

A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension.

Effects of different nitric oxide synthases on pulmonary and systemic hemodynamics in hypoxic stress rat model

Enhanced Aerobic Glycolysis by S-Nitrosoglutathione Via HIF-1α Associated GLUT1/Aldolase A Axis in Human Endothelial Cells

Impact of Endogenous Nitric Oxide on the Hydrogen Sulfide/cystathionine-Γ-lyase System in Pulmonary Artery of Hypoxic Rats

Skeletal Muscle Aldolase an Overexpression in Endotoxemic Rats and Inhibited by GSNO Via Potential Role for S-nitrosylation in Vitro.

Endogenous nitric oxide regulates heme oxygenase/carbon monoxide system in intrapulmonary arteries of hypoxic rats

Role of S‐nitrosoglutathione reductase (GSNOR) Dysregulation and Nitrosative Stress in Heart Failure With Preserved Ejection Fraction

Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension.

Induction of Lipocalin-Type Prostaglandin D Synthase in Mouse Heart under Hypoxemia

Effect of Hydrogen Sulfide on Oxidative Stress in Hypoxic Pulmonary Hypertension

Impact of nitric oxide on platelet-derived growth factor expression in intrapulmonary arteries of rats with hypoxic pulmonary vascular structural remodeling

Redistribution of SOD3 expression due to R213G polymorphism affects pulmonary interstitial macrophage reprogramming in response to hypoxia

Upregulation of DDAH2 Limits Pulmonary Hypertension and Right Ventricular Hypertrophy During Chronic Hypoxia in Ddah1 Knockout Mice

Nitric oxide augments signaling for contraction in hypoxic pulmonary arterial smooth muscle—Implications for hypoxic pulmonary hypertension

S-nitrosylation of Hsp90 promotes cardiac hypertrophy in mice through GSK3β signaling

New Nitric Oxide Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease

Exacerbated Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Animals with Loss of Function of Extracellular Superoxide Dismutase.